Last reviewed · How we verify
NCT04742816
Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients
Phase 4 trial testing IHX-CL measurements in Transgender in 42 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | University of California, San Diego |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 42 |
| Start date | 17 September 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- IHX-CL measurements
- Iohexol (IOHEXOL) — full drug profile →
Conditions studied
- Transgender — all drugs for Transgender →
- Renal Function — all drugs for Renal Function →
- Hormone Replacement Therapy — all drugs for Hormone Replacement Therapy →
Sponsor
University of California, San Diego
Who can join
Adults 18 to 100, any sex, with Transgender or Renal Function. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Will use a subset of the main study cohort of transgender or non-binary individuals to evaluate the relationships between self-reported exogenous hormone use, endogenous hormone values, renal biomarkers, drug levels and directly measured renal function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04742816
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transgender
Currently open trials in the same condition.
- NCT07075731 — Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy · recruiting
- NCT05334888 — Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach · recruiting
- NCT05318755 — China Gender-affirming Hormone Therapy Study · recruiting
- NCT04977765 — Cardiometabolic Health in Transgender Males · active not recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
- NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
- NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
- NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
- NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04742816 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
- Last refreshed: 3 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04742816.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing